These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 37945321)

  • 1. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family.
    Soler MF; Abaurrea A; Azcoaga P; Araujo AM; Caffarel MM
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37945321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer resistance mechanisms: challenges to immunotherapy.
    Hanna A; Balko JM
    Breast Cancer Res Treat; 2021 Nov; 190(1):5-17. PubMed ID: 34322780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy.
    Cini JK; Dexter S; Rezac DJ; McAndrew SJ; Hedou G; Brody R; Eraslan RN; Kenney RT; Mohan P
    Front Immunol; 2023; 14():1326927. PubMed ID: 38250068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.
    Jones SA; Jenkins BJ
    Nat Rev Immunol; 2018 Dec; 18(12):773-789. PubMed ID: 30254251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment.
    Yi P; Yu W; Xiong Y; Dong Y; Huang Q; Lin Y; Du Y; Hua F
    Mol Cancer Ther; 2024 Feb; 23(2):148-158. PubMed ID: 37988561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
    Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
    Front Immunol; 2022; 13():872295. PubMed ID: 35634282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
    Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
    Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
    Montero-Julian FA; Brailly H; Sautès C; Joyeux I; Dorval T; Mosseri V; Yasukawa K; Wijdenes J; Adler A; Gorin I; Fridman WH; Tartour E
    Clin Cancer Res; 1997 Aug; 3(8):1443-51. PubMed ID: 9815830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic inflammation, cancer development and immunotherapy.
    Wen Y; Zhu Y; Zhang C; Yang X; Gao Y; Li M; Yang H; Liu T; Tang H
    Front Pharmacol; 2022; 13():1040163. PubMed ID: 36313280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein.
    Chevalier S; Fourcin M; Robledo O; Wijdenes J; Pouplard-Barthelaix A; Gascan H
    J Biol Chem; 1996 Jun; 271(25):14764-72. PubMed ID: 8662918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity.
    Seclì L; Infante L; Nocchi L; De Lucia M; Cotugno G; Leoni G; Micarelli E; Garzia I; Avalle L; Sdruscia G; Troise F; Allocca S; Romano G; Scarselli E; D'Alise AM
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37117006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
    Boshuizen J; Pencheva N; Krijgsman O; Altimari DD; Castro PG; de Bruijn B; Ligtenberg MA; Gresnigt-Van den Heuvel E; Vredevoogd DW; Song JY; Visser N; Apriamashvili G; Janmaat ML; Plantinga TS; Franken P; Houtkamp M; Lingnau A; Jure-Kunkel M; Peeper DS
    Cancer Res; 2021 Apr; 81(7):1775-1787. PubMed ID: 33531370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.